Welcome to Amarin Corporation's conference call to discuss its third quarter 2022 financial results and operational updates. This conference call is being recorded October 27th, 2022. I would now like to turn the conference call over to Lisa DeFrancesco, Senior Vice President, Investor Relations and Corporate Affairs at Amarin. Good morning, everyone, and thank you for joining us. Please be aware that this conference call will contain forward-looking statements that are intended to be covered under the safe harbor provided by the Private Securities Litigation Reform Act. We may not achieve our goals, carry out our plans or intentions, or meet the expectations disclosed in our forward-looking statements. Actual results or events could differ materially, so you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change. Our forward-looking statements do not reflect the potential impacts of significant transactions we may enter into, such as mergers, acquisitions, dispositions, joint ventures, or any material agreements that we may enter into, amend, or terminate. For additional information concerning the risk factors that could cause actual results to differ materially, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2021, and our Form 10-Q for the quarter ended September 30th, 2022, which have been filed with the SEC and are available throughout the Investor Relations section of our website at www.amarincorp.com. We encourage everyone to read these documents. This call is intended for investors in Amarin and is not intended to promote the use of Vascepa. An archive of this call will be posted on Amarin's website in the Investor Relations section. Karim Mikhail, Amarin's President and Chief Executive Officer, will lead our discussion, and Tom Reilly, Amarin's Chief Financial Officer, will provide a more detailed review of our third quarter 2022 financial results. After prepared remarks, we will open the call to your questions. I remind you that multiple audiences typically listen to calls of this nature, including existing investors, potential new investors, employees, current and potential collaborators, and current and potential competitors. As always, in this call, we will attempt to provide constructive information without compromising our competitive and strategic positioning. I will now turn the call over to Karim Mikhail, President and Chief Executive Officer of Amarin. Karim? Thank you, Lisa. Good morning and thank you all for joining us today. We began this year embarking on a bold strategy to grow and expand globally. We focused our three-dimensional growth strategy, breadth or geographic expansion, height representing diversification, and depth or core operational evolution. Now, with 2022 nearing a close, and despite the significant headwinds and challenges faced early in the year, we are pleased to report that we made significant progress across our key priorities, and we continue to achieve what we committed to. Most importantly, we have turned around our cash burn levels as we strengthened our foundation through operational excellence, strengthened our leadership team, and laid the groundwork for a true transformation of Amarin in 2023. I'm going to begin today by discussing the results of our cash preservation initiatives because I believe this progress is significant and critical to support our future growth and expansion plans. There are two key initiatives that were central to our effort and the progress delivered. First, in June, we took swift action announcing an extensive cost savings plan to reduce our operating expenses by $100 million over 12 months. This initiative was comprehensive and involved cost reductions across the entire organization, and we are beginning to realize these savings this quarter exactly as planned. Second, beginning last quarter, and as part of our company-wide focus on operational excellence, we took steps to evolve our supply chain strategy and amend our supplier agreements to align supply arrangements with current and future demand within our U.S. business. These initiatives, which Tom will discuss in more detail shortly, have resulted in significantly lower cash burn quarter-over-quarter. In fact, this quarter we are cash positive, excluding restructuring charges. Also contributing to the improvement of our cash runway is the consistent stabilization of the U.S. revenue over the last three quarters, despite continued pressure from additional generic competition. We achieved this by refocusing our core U.S. team efforts to sustain and support the Vascepa brand. Additionally, and as a result of the difficult decisions made at the right time to reduce commercial footprint in the U.S., we remain highly profitable, supporting future international growth. As I look at our third quarter results and in the U.S. business, I'm pleased to say our strategy is working. In the third quarter of 2022, we recorded $89.9 million in total net revenue, including $87.9 million in U.S. product sales, largely unchanged from last quarter, despite the continued pressure from generic competition and the restructuring effort we announced in June, which reduced our sales and marketing efforts and commercial footprint in the U.S. significantly. This is now the third consecutive quarter with relatively consistent revenue performance despite continued generic competition, which is unprecedented in the industry. The third quarter performance was achieved with a more efficient footprint and resources, which speaks to the strength and efforts of the full U.S. team. Our steps to focus on promoting our brand are working. Based on the latest prescription trends, we are maintaining current share at roughly 60% of the total IPE market on a quarterly basis. We will continue to closely monitor the market dynamics in the U.S. and remain ready to adjust as necessary wherever possible. With the stabilization of the U.S. business and the bold cash preservation actions we have taken, we have successfully extended our cash runway to ensure we can fund our expansion plans. While I began today's discussion with the recent actions dedicated to strengthening our financial foundation and preserving our U.S. revenues, we remain laser-focused on our core future objective, which is global growth and expansion for Vascepa in Europe and internationally, as this is the key to shareholder value creation. 2022 has been about laying the foundation for our future across Europe, and we are now beginning to see this take shape before our eyes. We are now officially on the market and in commercial launch stage in the U.K. and Sweden. We recently received final positive national reimbursement in Finland and Northern Ireland at a price in line with our recent U.K. pricing. We also received individual reimbursement in Austria with a process underway for national reimbursement. Although there are no set timelines in any of the remaining major markets, we are now negotiating reimbursement and are now in the advanced stages in all markets. In particular, price negotiations are nearing conclusion with Spain's Ministry of Health, which could allow for a possible pricing and reimbursement decision shortly before the end of 2022. In the Netherlands, we received a positive scientific assessment by the National Health Care Institute, ZIN, for reimbursement and are beginning pricing negotiation with the Dutch Ministry of Health. In Italy, we achieved the key milestone of a positive scientific assessment, allowing for our dossier to advance from the scientific assessment phase into the pricing and reimbursement negotiation phase with the Italian authorities. Our strategy has always been around building a strong, diverse, and sustainable revenue stream in Europe. This is why we have filed in 13 markets simultaneously since 2021 and are now in the mid to late stage reimbursement negotiations in France, Italy, Spain, the Netherlands and Norway. This progress thus far, and specifically the level of reimbursement price we have received, acknowledges the value of Vascepa and our ability to demonstrate this value to payers across Europe. Turning to commercialization efforts in Europe. In the U.K., our launch is underway since mid-October and is progressing well and in line with our expectation based on our deep understanding of the market. To provide some context on the U.K. market and how it operates, there are three distinct tiers of healthcare administration in England. NHS England, or the National Health Service, which provides guidance on usage. Next, the integrated care systems are consolidations of organizations that plan for service delivery and funding. The final tier are local accounts with formularies which list the reimbursed products. As you recall, since receiving our final approval in July, we have been following the typical process while we await approval for public funding. We spent the first 90 days post-approval focused on gaining formulary access through education, medical and scientific engagement, implementing formulary guidelines, and building awareness and adoption through multiple educational and commercial channels. We are simultaneously building a strong team in the U.K. As I mentioned earlier this month, public funding is now becoming available and we are transitioning to the commercial focus. The number of formulary inclusion of Vascepa continues to track ahead of analogs and is improving weekly, thanks to the clear stepwise approach to achieve both formulary listing and medicines pathway inclusion. We are proud that Vascepa is making its way as a new standard of care to reduce the risk of CV events beyond LDL-C management in England. We will be updating investors with our U.K. performance to ensure everyone can keep track of our progress versus benchmarks over the next quarters. Turning to the rest of Europe, we're also progressing in other major markets, as well as continuing to advance our reimbursement discussions with national health authorities in Norway, Italy, France, the Netherlands, Portugal and Switzerland, where we have recently submitted and are now on file for reimbursement discussions. We remain on track to receive reimbursement decisions in up to eight countries and to launch Vascepa in up to six European countries this year. We remain confident that 2023 will be the beginning of strong, sustainable revenue generation towards $1 billion-plus peak opportunity in Europe. Our progress continues beyond Europe, where we continue our plan to file in up to 20 countries through 2024. I'm pleased to say thus far we have filed in 10 markets with the potential for a number of others before year-end and into early 2023. Specifically, Amarin's marketing authorization submissions for Vascepa have been achieved in Hong Kong, Saudi Arabia and Bahrain, and applications remain pending in a number of other markets, including Australia and New Zealand, which are continuing to advance their local procedures. We've also confirmed that our regulatory filings are now actively under review in South Africa and other markets. This is critical as we continue our search for the right partner in all those international territories where we do not plan to build our own infrastructure. Our current partners continue to make progress as well, including Eddingpharm, our partner in China, recently stated that they have received confirmation that the Chinese government has completed the product testing and has initiated the final review period prior to approval. This final review began earlier this month and has a clock of up to 67 business days. Our partner has communicated to us that they anticipate an approval could still be achieved before year-end. In Canada, HLS Therapeutics Inc. has obtained reimbursement from all major public payers, gaining access to the vast majority of eligible patients in Canada. They continue to be in the launch phase in the public sector. We remain confident in the multi-billion dollar global market opportunity for Vascepa in Europe and internationally, and we continue to invest in our data and evidence building of IPE now with a global focus. Following a leading presence at the European Society of Cardiology Congress over the summer, we remain committed to maintaining a strong presence at important medical meetings, including the upcoming Canadian Cardiovascular Congress, American Heart Association, and the International Society for Pharmacoeconomics and Outcomes Research in Europe, which is a premier congress to discuss healthcare outcomes research. Our data was selected for presentation demonstrating the cost effectiveness of Vascepa in treating cardiovascular outcomes in the Netherlands. Lastly, we continue to develop our fixed dose combination, which ensures our ongoing progress with this important program that combines Vascepa with a statin. To summarize our progress year to date, we are experiencing stable business trends in the U.S., taking important steps to preserve our cash. Our global expansion plans remain on track, and we are continuing to focus on building data evidence and furthering our pipeline for the future. With that, I'll turn it over to Tom to talk more about our progress and strong results this quarter. Tom? Thank you, Karim. Good morning, everyone. I am pleased to report our financial performance for the third quarter of 2022. I'm glad to note when excluding the $25 million Q2 restructuring payments made in Q3, we are cash positive in the third quarter of 2022. Let me begin with our revenue performance. For the third quarter of 2022, we reported total net revenue of $89.9 million, including net product revenue of $89.2 million, a decrease of 37% compared to the third quarter of 2021. U.S. product revenue was $87.9 million, a decline of only $2.8 million versus the second quarter of 2022, reflecting relatively stable trends in both volume and price. Beginning last quarter, we are not investing to grow the IPE molecule in the U.S. market, but are investing in sustaining and supporting the Vascepa brand and prescriber base we have today in the U.S. While we are pleased with the relatively stable trends, we expect volumes and price will continue to experience some pressure throughout this year and into next year. The results included international product revenue of $1.3 million, which includes European product revenue of $0.7 million. Cost of goods sold for the three months ended September 30th, 2022 was $27 million, compared to $30.2 million in the corresponding period of 2021. During the three months ended September 30th, 2022, Amarin continued the initiative, which began last quarter, to take steps to amend supply agreement to align supply arrangements with current and future market demand, resulting in a charge of $3.1 million this quarter. The renegotiation of these agreements is a very important step in our cash preservation strategy and lowering our future inventory purchases. Excluding the impact of this item, gross margin was 73% for the three months ended September 30th, 2022, compared to 79% in Q3 2021. Moving to operating expenses. During the third quarter of 2022, we reported expenses of $68 million compared to $124.9 million in the third quarter of 2021, a decrease of $56.9 million or 46%. The results this quarter include a $4.4 million restructuring expense related to the discontinuation of operations in Germany, and the third quarter of 2021 included a $14.1 million restructuring charge related to the U.S. The decrease compared to last year is related to the cost-saving initiatives that were announced in September of 2021 and in June of 2022. These savings were partially offset by our investments in growth and expansion in Europe. Operating expenses decreased $38.5 million or 36% versus the second quarter of 2022. This is a $28 million decrease versus Q2 2022, excluding net restructuring charges and stock compensation expense. We began to realize the benefits of the June cost reduction this quarter, and we expect to continue to realize the benefit through mid-2023, totaling $100 million in savings. The U.S. business continues to be profitable from a contribution margin perspective and provides all the necessary financial support for the expansion into Europe and other geographies around the world. Under U.S. GAAP, Amarin reported net loss of $5.1 million for the third quarter of 2022, or basic and diluted loss per share of $0.01. As of September 30th, 2022, Amarin reported aggregate cash and investments of $306 million, demonstrating a significantly lower cash burn relative to earlier quarters in 2022. We have taken significant steps to strengthen the company operationally. We plan to continue to manage our cash prudently relative to business performance. With the recent operational initiatives and the stabilized revenue trends in the U.S., we have significantly lowered our cash burn and believe our current available cash and resources, including U.S. profitability, are adequate to support continued operations, including European launch activities. Now I will turn the call back to Karim for closing remarks. Karim? Thank you, Tom, for that financial overview and our results during the third quarter. I'm pleased with the results this quarter and thus far this year. We have made a great deal of progress despite the many challenges. As we look to the remainder of 2022 and into the early part of 2023, we will continue to ensure we remain operationally strong from a cash perspective, dedicated to driving our global expansion plans with the launch materializing in Europe and continuing to build evidence globally to support Vascepa. We remain focused on our bold vision to stop cardiovascular disease from being a leading cause of death worldwide. With that, operator, we are ready to take questions. Ladies and gentlemen, the floor is now open for questions. If you have any questions or comments, please press star one on your phone at this time. We ask while posing your question, you please pick up your handset if listening on speakerphone to provide optimum sound quality. Please hold while we poll for questions. Your first question for today is coming from Michael Yee. Please announce your affiliation, then pose your question. Hey, good morning, Karim. It's Michael Yee from Jefferies. Can you hear me? Hi, good morning, Mike. Hey, great. We had two questions. First, congrats on the U.S. It looks to be quite stable, which is great. Can you remind me, do you guys expect continued generics to come in at some point as supply opens up? Or do you also have exclusive contracts and preferred contracts, which is also helping? Can you remind me how that dynamic works in the U.S.? That would give us some visibility there. Secondly is on Europe. I know that you're working on different regions and they're coming on. Can you just describe how you expect the cadence and importantly, the investment or the spend to grow there, as you get through 2023? Thank you. Thanks, Mike. We'll start with the first question with regards to generics. As a reminder, this was a very unusual generic launch sequence. We've had one in October of 2021, then we've had one six months later, then the third one came in Q1 2022. Apotex launched in February. We have also seen Teva launch the 500 milligram just two weeks ago in this last quarter. We still see new generic entrants. Now, so far, Teva only came with the 500 milligram, which is really 2% of the market. We'll have to wait and see when they come, if they come, with the one gram. I think what we can share is that even with three on the market, we've seen a stabilization of our prescription and our revenue in the first, second and third quarter of this year. You know, we keep tracking this. The situation is dynamic. Having said that, we feel confident that where we stand today, we did stabilize the revenue. We are losing in, you know, low single digits in prescription and you know, things are progressing as we plan them. Now, of course, we have to be ready for any possible scenario, right? We could have, you know, different events coming up, and for that, we have multiple sort of scenarios ready. We are ready to go for an authorized generic and press on the button and immediately switch if we need be, and even other plans, you know, that we could implement in that case. That's for the U.S. We feel confident the situation is so far stable and we continue our efforts with our core enforcement team in the U.S. Moving on to Europe, as you've seen, you know, we have had consistent pricing and reimbursement, positive decisions in Europe, right? We started with Sweden at, you know, the price of $180 per month, almost $2,000, you know, annually. We've had the U.K., which is far more sophisticated, more complex system that also agreed to the same price. This quarter, we announced a third country, which is Finland, announcing also approval for this price. Just, you know, to give even more color and detail, Finland initially rejected the file completely, and we had to resubmit from scratch, and we still got the price we asked for from Finland aligned with the other markets. Things are progressing well. You've just heard also that we, you know, we received a positive, you know, scientific assessment from, you know, the Netherlands. We received a positive assessment from Italy, and we are in final price negotiation in Spain. You know, I don't wanna say we're accelerating, but things are progressing in the right direction with regards to pricing reimbursement. At the same time, we are starting now commercial launches, right? We're starting commercial launches in the U.K., you know, and in Sweden, and things are progressing as planned. We believe we will be able to share some U.K. metrics in the next quarters to ensure that, you know, all investors and shareholders are updated with our performance in Europe. Thank you. Thank you. Your next question is coming from Georgi Yordanov. Please announce your affiliation, then pose your question. Hi. Thank you so much for taking our questions. This is Georgi Yordanov from Cowen and Company. Maybe just to follow up on the previous question. Just on the generics, do you have any idea or thoughts around like why their share has plateaued around that 10%-15%? And your renegotiated supply agreement that you mentioned, does that kind of maybe provide additional capacity for those generics? And then I just have one follow-up. Okay. You know, I don't know which company you really quoted as too flat in terms of generic share. I mean, some of them are at 15, some are at less. You know, the reality is, you know, this is now an open market and every you know, generic is going after its business. We do not know, you know, why their share is where it is. We know what we are doing, right? What we are doing is we're fully focused on brand promotion. We're not investing a dollar, you know, to grow the molecule, which ends up going to generic business, right? That's what we're focusing on. We're making sure we have, you know, an appealing offer to our plans so that they continue to work with us because we have a sustained supply with, you know, efficient cost of goods. That's what we are doing. So far, as you can see, it is working, right. We are stabilizing the erosion from a share perspective. You know, on quarterly basis, we are at 60%, which is great. Now, you know, what can happen tomorrow? Look, for the moment, our strategy is working. We continue to monitor. Is there enough supply for the generics? You bet there is enough supply, right? So if there is an estimate or an assumption that generics are not selling because they don't have enough supply, I can tell you know, it takes 18 months to have enough supply. We've been beyond the 18 months with generics on the market. There is enough supply beyond what anybody probably needs. It's not a question of supply. Now, with our renegotiated, you know, arrangements, you know, this was necessary from a cash burn perspective, right? You see the result and the very positive impact on our cash burn because that's an initiative that's here to stay. This is not something that you do that in a way you eliminate cash burn for a quarter and then it's gonna come back. In reality, this is gonna be a stable situation. We have enough inventory for the U.S., and we don't believe that the extra supply that's going to anybody else can really change the story because there was already enough supply on the market even before that. That's not changing really the situation. Thank you. That's actually very helpful. My follow-up was just as we think about the positive decision in the upcoming launch in the U.K., do you kind of like as we try to understand the size of that specific market, in particular, do you have any kind of like data on usually what percentage of pharmaceutical sales in Europe come from the U.K.? How should we be thinking about the ramp-up there, in terms of the launch? Yeah. The U.K. is definitely one of the top five, right? You're talking about a population of close to 70 million. It's, you know, a big market. In general, it, you know, will usually be number three, number four, depending on the uptake. Because it's a highly scientific market, by the way, you know, prescribers tend to be skeptical, and that's an advantage for us because we have evidence, so we believe it's a market that we can do well early on. So far, we can see that we are tracking better than analogs in terms of formulary inclusion. That's the most important proxy that tells you how much uptake you're gonna get 'cause your product has to be listed and has to be funded on the local formulary. So far, we're ahead of, you know, analogs. It is a significant market. We are, you know, confident that this is gonna be an important launch and, you know, and again, we continue to prepare, and we will update over the next quarter with the results. Thank you. That's very helpful. Congrats on the progress. Thank you. Your next question for today is coming from Roanna Ruiz. Please announce your affiliation, then pose your question. Hi. Yes. Roanna Ruiz from SVB Securities. Morning, everybody. I wanted to check in a little bit about Germany and the arbitration decision. Was curious if you still expect to be on track for a mid-November update there? Yeah. On Germany, the timing of the arbitration is mid- to end November. You know, as you've seen from prior disclosures, we already took all the actions needed basically to, you know, eliminate cash burn in Germany, waiting for a decision. In general, you know, arbitrations usually do not, you know, lead to a positive decision. Let's be very real. That's, you know, that's usually a low probability of success. And if you succeed, usually there is risk in, you know, lowering the price, which will have impact on other markets. The decision we took, which is to say, "Look, we're gonna suspend operations in Germany," was to protect the price in the U.K. and Sweden and Finland, the price we're negotiating in Spain, as you can imagine, and other prices. Because the value of Germany as a country, let's assume that a large market is 15% of total Europe, right? If that country is gonna give you a price 15% less than your average European, you are at a loss, right? You know, we are not gonna accept a price less than 15 because so far we have a very consistent approval pricing level at a European level, right? I mean, if you look at our Finland price, I mean, it looks today maybe just slightly lower than the U.K.. In fact, it's only because of exchange. In reality it's higher, you know, based on earlier calculations. That's really for Germany and arbitration. Got it. Yep, that makes sense. I also want to check in on your fixed-dose combination work for Vascepa with a statin. Any updates on how that's progressing? Could we expect any data or program updates later this year or into 2023? Yeah. We're working very hard on this initiative, and you've seen that we're making a lot of effort to keep our disclosures to a minimum because, you know, there is a lot of, you know, a lot going on that we need to keep sort of confidential until the right moment. Once we will be ready to communicate, we will, and it is over the next, you know, quarter two that we are gonna come out with an update. There is a lot going on. It's just that it's not the right time to disclose it at this stage. The program continues and progresses successfully. Understood. Helpful. We'll keep watch for that. Thanks. Thank you, Roanna. Your next question for today is coming from Louise Chen. Please announce your affiliation, then pose your question. Hi. Good morning, everyone. This is Kareem Zaghloul on for Louise Chen from Cantor Fitzgerald. Thank you for taking our questions. First question is: what do you expect to be the biggest catalyst in the next 12-18 months? Second question is: on the $100 million cost savings through mid-2023, can you speak more about the pace of the saving realization? Should we expect more savings to be realized early on, say later up this year or more sort of beginning of next year? Our last question is: you've guided the commercial launch in Hong Kong for some time this year, which is a separate track with China. Is there any updates here? Thank you so much. Sure. Thank you. I'll take the first question about the most important catalyst. I believe the most critical one is for us to achieve pricing reimbursement in another large market. You know, this is really what's gonna drive shareholder value. The price that we have in the U.K. is very positive, but I think the key question is, with the situation in Germany and the challenges we face, can we actually achieve, you know, the same pricing and reimbursement level in other larger markets? That's a very critical one, and we are working to deliver on this over the next few months, you know, in the very near term, because we are in very active pricing negotiation with the Spanish government. To me, that's one of the most critical, you know, key milestones. Another one would be that we come out with an update on our fixed-dose combination. I think there's very little known about this at this stage. When we will go public with this, I mean, many of the shareholders will understand the value that this fixed-dose combination really brings short and long term, you know, for the business. That's really at a high level. Now, for the question on cost savings and sequence, I'll leave Tom sort of give more, you know, detail on that. Sure. Thanks, Kareem Zaghloul, for the question. We committed to $100 million of cost savings through mid-2023, and you'll see for this quarter, we realized just about approximately $25 million. The way to think about this on a moving forward basis over the next three quarters is within that range on a quarterly basis. We'll deliver the $100 million. I think the other thing just to keep in mind that they did really timely with our investments in Europe as we're getting reimbursement. As reimbursement comes in, obviously the spend will adjust. If it doesn't come in on the time we're expecting, then we'll adjust accordingly as well. We're being very prudent on that as we continue with our cash preservation. Yeah. Finally, on Hong Kong and China. You know, as you know, Asia is still, by the way, severely impacted by COVID and things sort of restart in multiple. We are in discussions to see what is the best sort of moment to go ahead with the launch. Hong Kong is a small market. Honestly, we're focusing more on the larger ones that will make a big difference in creating shareholder value. As you've seen from our disclosures, we put in a lot of information about updates on, you know, filing in other Asian markets because we believe it's so critical when we are active in Asia that we're active in multiple territories because they do, you know, synergize our effort at the end of the day. Thank you for the question. Thank you so much. Your next question for today is coming from Th-An Ho. Please announce your affiliation, then pose your question. This is Daniel from JPMorgan. Thank you for taking our questions. Karim, you highlighted a potential peak opportunity of $1 billion in Europe. Does that assume launch in Germany as well? Within Germany, you sort of mentioned that in Finland you got rejected, but then you still managed to get an approval. You have outlined a process by which you're trying to submit a dossier here for that process to restart again. Maybe can you give us a little bit detail on what the process involved and what type of new clinical evidence can you provide to support the therapeutic benefits of Vascepa? I have one follow-up question. Okay, with regards to Germany, yes, we confirm based on the pricing and reimbursement levels that we are getting in Europe today, that we believe that the peak is, you know, upward of $1 billion, right? Even without Germany, right? Now the way it's gonna work is the following. You know, we currently today, you know, in arbitration, we'll have to wait to see how the arbitration decision goes. There has been one precedent on the German market where a product that, you know, received a negative decision that went back and applied. In that case, they actually used real-world evidence data to support the clinical benefit. I'm not saying this is exactly what we're gonna do, but that's. I'm just mentioning that there is a path, there is a very specific path to resubmitting a file in Germany. Having said that, you know, the most important part today is to focus on the other larger markets, making sure that we get, you know, pricing reimbursement in Spain, making sure we get pricing reimbursement in Italy and France because that's really what's gonna drive the value overall. Got it. Makes sense. In terms of generics in the U.S. beyond supply issues, we've heard that pricing of APIs have become more competitive for the generic manufacturers. Do you believe there's any impact from that on the stability of Vascepa? Look, I mean, there was a period where pricing was stable. Then there was a period that pricing was unstable beginning of this year. It's difficult to predict, right, you know, at what price and whether there will be. But look, it would be unreasonable not to think that there will be future price competition, right? If you have more generics, theoretically you're gonna have, you know, more price competition. We have taken that into account in the way we look at the business, in the way we sized our footprint. I remind people that a year ago, our footprint was 780 people. Today our footprint is 75 reps. We are at a 10% footprint. That's why we believe we are still driving significant contribution margin from the U.S. no matter what the price impacts are or volume impacts are. If we need to, we have an authorized generic plan ready with a lot of supply that's just ready to go to the market. That's why you've seen us confident in coming out and saying we're extending our cash runway because we believe in whatever scenario we're gonna be, we will be able to get to, you know, revenue from Europe with our investments and with.the contribution margin we're getting from the U.S. Got it. Last question for me. Understanding that you haven't disclosed much about the fixed dose combo, do you believe it can provide any new patent protection to Vascepa by any chance in the U.S.? you know, the, there is a question of patent, but there is also a question of other protection. you know, today, let's face it, this opportunity is gonna be very, very critical for Europe, right? Because this is where, you know, we're talking about the billion-dollar opportunity. This is where we're creating shareholder value. most of our efforts are really making sure that that's gonna add additional, right, opportunity to Europe, which I believe everybody is seeing moving in the right direction. What will it provide to the U.S. will depend very much on where the generic market is gonna be when we come out with a fixed dose combination, right? Which is gonna be. You know, a you know, a couple of years or more from now. you know, this is really gonna be focused mainly on Europe and international markets, and we're gonna talk more about it when we are ready to disclose more details. Great. Thank you very much. Thank you, Dan. Once again, if there are any questions or comments, please press star one on your phone at this time. Your next question for today is coming from Paul Choi. Please announce your affiliation, then pose your question. Hi. Thanks. Paul Choi with Goldman Sachs. A quick financial question for Tom, just one point of clarification with regard to the $100 million in savings that you're targeting through mid-2023. How much of that is incremental savings from the current run rate versus the discontinuation of operations from Germany? Can you quantify that for us? Sure, Paul. Thanks for the question. The way we've previously disclosed and we're committed to, the way we look at this is we looked at the full year of 2021 as our base, right? Which was approximately $450 million of operating expenses. We've committed that the $100 million of savings that we anticipate through mid of 2023 will be based off that $450 million benchmark. Okay. Can you repeat the question? Well, I'm just trying to understand how much is like from, you know, your discontinuation of operations in Germany versus your, you know, 2021 base of that $100 million target. It's baked in. It's part of the overall net investments related to Europe. Okay. Okay. Okay. Great. Thanks for that. A follow-up for Karim. You know, you talked about some additional partners for geographies where you're not gonna necessarily be directly commercializing yourself in ex-U.S. markets. Can you maybe just, you know, give us a sense as to when those partnerships or agreements might potentially be finalized? And then, you know, how you're thinking about the incremental launch timing in those external markets relative to the U.S. Thanks, Paul. We're trying to align the dates of these partnerships with the dates of regulatory approvals, right? Because that's really when it becomes critical. For the moment, we did discuss and, you know, engage with local partner in some of the larger, you know, markets internationally. We did engage with regional partners in other regions like Asia or Latin America, but we're also engaging with global partners that can take multiple territories, you know, at an international level. We're working very hard to align those approvals. We're gonna have some approvals by end of this year, some next year and some 2024. That continues to be a top priority because we believe that that's just gonna open another revenue stream with no basic cost, you know, no burn on our side. It's definitely a priority, and hopefully we will be announcing something by early 2023. Okay. Thank you very much for taking our questions. Thank you. That is all the time we have for questions today. I would like to turn the floor back over to the Amarin management team for closing remarks. I just wanna thank everyone. I mean, this has been, you know, a very solid quarter coming up from, you know, Q1 and Q2 with the U.S. revenue stabilization. The fact that we are, you know, cash positive, excluding restructuring charges, and we continue to make strides in pricing and reimbursement in Europe and now launching effectively in one of the largest countries. We thank you, and we look forward to speak in the next quarter and to update you on our results. Thank you all. Thank you, ladies and gentlemen. This does conclude today's event. You may disconnect your phone lines at this time and have a wonderful day. Thank you for your participation.